Jasper Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Jasper Therapeutics Inc.
- Former names
- Amplitude Healthcare Acquisition Corp
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Redwood City
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- JSPR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001788028
- EIN
- 84-2984849
Board of directors
-
Anna Louise French · DirectorSince 2023
-
Chris Nolet · DirectorSince 2023
-
Jeetinder Singh Mahal · Director · CEO and PresidentSince 2026
-
Judith Anne Shizuru · DirectorSince 2023
-
Kurt Von Emster · DirectorSince 2023
-
Lawrence Otto Klein · DirectorSince 2023
-
Patrick J. Crutcher · DirectorSince 2026
-
Ron Martell · Director · President, CEO and DirectorSince 2023
-
Scott C. Brun · DirectorSince 2023
-
Svetlana Lucas · DirectorSince 2024
-
Thomas G. Wiggans · DirectorSince 2023
-
Vishal Kapoor · DirectorSince 2023
-
William Lis · DirectorSince 2023
Chief executives
Ron Martell
· President and CEO
Dates unknown
Jeetinder Singh Mahal
· CEO and President
Dates unknown
Director election results
Annual meeting of July 3, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
97.9%
-
99.0%
-
99.5%
Board connections
7 of this board's directors also sit on 9 other boards.
- via Patrick J. Crutcher
- via Thomas G. Wiggans
- via Chris Nolet
- via Scott C. Brun
- via Lawrence Otto Klein
- via Lawrence Otto Klein
- via Thomas G. Wiggans
- via William Lis
- via Svetlana Lucas
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 22, 2025 | Thomas G. Wiggans Director | Open-market purchase | +41,000 | $2.43 | $99,630 |
| Sep 22, 2025 | Svetlana Lucas Director | Open-market purchase | +20,000 | $2.43 | $48,600 |
| Sep 22, 2025 | Ron Martell Director, Officer (President and CEO) | Open-market purchase | +41,000 | $2.43 | $99,630 |
| Sep 22, 2025 | Judith Anne Shizuru Director | Open-market purchase | +41,000 | $2.43 | $99,630 |
| Dec 12, 2024 | Mahal Jeetinder Singh Officer (Chief Operating Officer) | Option exercise | +900 | $7.10 | $6,390 |
| Dec 12, 2024 | Mahal Jeetinder Singh Officer (Chief Operating Officer) | Open-market sale | −900 | $22.11 | $19,899 |
| Sep 12, 2024 | Mahal Jeetinder Singh Officer (Chief Operating Officer) | Option exercise | +900 | $7.10 | $6,390 |
| Sep 12, 2024 | Mahal Jeetinder Singh Officer (Chief Operating Officer) | Open-market sale | −900 | $21.23 | $19,107 |
| Jun 12, 2024 | Mahal Jeetinder Singh Officer (Chief Operating Officer) | Option exercise | +900 | $7.10 | $6,390 |
| Jun 12, 2024 | Mahal Jeetinder Singh Officer (Chief Operating Officer) | Open-market sale | −900 | $24.16 | $21,744 |
| Jun 7, 2024 | Tucker Edwin Jonathan Officer (Chief Medical Officer) | Grant or award | +400 | $4.17 | $1,668 |
| Mar 12, 2024 | Mahal Jeetinder Singh Officer (Chief Operating Officer) | Option exercise | +900 | $7.10 | $6,390 |
| Mar 12, 2024 | Mahal Jeetinder Singh Officer (Chief Operating Officer) | Open-market sale | −900 | $26.44 | $23,796 |
| Feb 8, 2024 | Abingworth LLP 10% owner | Open-market purchase | +190,000 | $12.95 | $2,460,500 |
| Feb 8, 2024 | VENKATARAMAN BALAJI 10% owner | Open-market purchase | +350,000 | $12.95 | $4,532,500 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.